Sichuan Baili (Biokin, SystImmune)

China

FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
5 in Phase 3
6 in Phase 2
Next date
izalontamab brengitecan, Phase 3 trial completes
Drugs
19
in active trials · 22 in all
Trials
138 active
143 since 2021

Drugs19

DrugHow it worksPartnerStageNext dateDetails
EGFR/HER3 bispecific antibody-drug conjugate
Bristol Myers Squibb
Phase 3 Nov 2026soonPhase 3 trial completes
—
Phase 3 Nov 2026soonPhase 2 trial completes
HER2-targeted antibody-drug conjugate
Phase 3 Dec 2026Phase 1/2 trial completes
—
Phase 2/3 Dec 2027Phase 2/3 trial completes
BL-M14D1not checked
—
Phase 3 Dec 2027Phase 2 trial completes
—
Phase 2 Nov 2026soonPhase 2 trial completes
—
Phase 1/2 Dec 2026Phase 1/2 trial completes
—
Phase 1/2 Dec 2026Phase 1/2 trial completes
—
Phase 2 Dec 2028Phase 1/2 trial completes
—
Phase 2 Dec 2028Phase 2 trial completes
—
Phase 1/2 —
—
Phase 1 Dec 2026Phase 1 trial completes
—
Phase 1 Jun 2027Phase 1 trial completes
—
Phase 1 Nov 2027Phase 1 trial completes
—
Phase 1 Dec 2027Phase 1 trial completes
—
Phase 1 Dec 2027Phase 1 trial completes
—
Phase 1 Oct 2028Phase 1 trial completes
—
Phase 1 —
—
Phase 1 —

About

No active trial
FOLFIRI Protocol, FOLFOX Protocol, SI-F019
SEC filings
None: it does not file with the US SEC
Registry names
2 names in ClinicalTrials.gov
Sources
ClinicalTrials.gov updated 16 Nov 2026 Industry-sponsored drug trials since 2021 · Logos provided by Logo.dev

Follow Sichuan Baili (Biokin, SystImmune)

Following is part of Solo: you see every change to Sichuan Baili (Biokin, SystImmune) the day it happens.

Solo

$49a month

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in